1. Academic Validation
  2. Tespa1 deficiency reduces the antitumour immune response by decreasing CD8+T cell activity in a mouse Lewis lung cancer model

Tespa1 deficiency reduces the antitumour immune response by decreasing CD8+T cell activity in a mouse Lewis lung cancer model

  • Int Immunopharmacol. 2023 Sep 1;124(Pt A):110865. doi: 10.1016/j.intimp.2023.110865.
Ruhui Yang 1 Mingyue Yang 2 Zehua Wu 3 Bingjin Liu 4 Mingzhu Zheng 5 Linrong Lu 6 Songquan Wu 7
Affiliations

Affiliations

  • 1 School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, Taizhou 318000, China; Department of Pharmacology, Lishui University School of Medicine, Lishui 323000, China.
  • 2 The First Clinical Department, China Medical University, Shenyang 110122, China.
  • 3 Faculty of Science and Engineering, University of Nottingham, Ningbo, 315000, China.
  • 4 School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, Taizhou, 318000, China.
  • 5 Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, 210003, China.
  • 6 Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  • 7 Department of Immunology, Lishui University School of Medicine, Lishui 323000, China. Electronic address: zjlswsq@163.com.
Abstract

Thymocyte-expressed, positive selection-associated 1 (Tespa1) is a key molecule in T-cell development and has been linked to immune diseases. However, its role in antitumour CD8+T cell immunity remains unclear. Here, we demonstrated that Tespa1 plays an important role in antitumour CD8+T cell immunity. First, compared with wild-type (WT) mice, Lewis lung Cancer cells grew faster in Tespa1 knockout (Tespa1-/-) mice, with reduced Apoptosis, and decreased CD8+T cells in peripheral blood and tumor tissues. Second, the proportion of CD8+T and Th1 cells in the splenocytes of Tespa1-/- mice was lower than that in WT mice. Third, Tespa1-/- CD8+ tumor-infiltrating lymphocytes (TILs) showed weakened proliferation, invasion, cytotoxicity, and protein expression of IL-2 signalling pathway components compared to WT CD8+TILs. Furthermore, PD-1 expression in CD8+TILs was higher in Tespa1-/- than in WT mice. Lastly, CD8+TILs in WT mice improved the antitumour ability of Tespa1-/- mice. In conclusion, these findings suggest that Tespa1 plays a critical role in the tumor immune system by regulating CD8+T cells.

Keywords

Antitumour immune; CD8(+)T cell; Lung cancer; Mouse; Tespa1.

Figures
Products